Disease · MONDO_0005642

atopic conjunctivitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. atopic conjunctivitis. Diseases, record MONDO_0005642. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005642

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: atopic conjunctivitis; Open Targets
Open Targets ID: MONDO_0005642; Open Targets
Other names: Conjunctivitis, Allergic, allergic conjunctivitis, allergic conjunctivitis (disease), allergic form of conjunctivitis (disease); Open Targets
Disease Ontology: DOID:11204; Disease Ontology
NCI Thesaurus: C34506; NCI Thesaurus
Highest stage of its drugs: Approval, for 28 of its 47 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs47

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OLOPATADINE HYDROCHLORIDE	CHEMBL1719	Small molecule	Approval	DailyMed and PMDA	25	16	16	Drugs and targets
OLOPATADINE	CHEMBL1189432	Small molecule	Approval	EMA Human Drugs and TTD	10	8	8	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	12	7	7	Drugs and targets
BEPOTASTINE BESYLATE	CHEMBL1201759	Small molecule	Approval	DailyMed	8	7	7	Drugs and targets
EPINASTINE HYDROCHLORIDE	CHEMBL1200491	Small molecule	Approval	DailyMed and PMDA	13	6	6	Drugs and targets
LOTEPREDNOL ETABONATE	CHEMBL1200865	Small molecule	Approval	DailyMed	9	6	6	Drugs and targets
KETOTIFEN	CHEMBL534	Small molecule	Approval	TTD	6	5	5	Drugs and targets
ALCAFTADINE	CHEMBL1201747	Small molecule	Approval	DailyMed and TTD	6	2	0	Drugs and targets
PREDNISOLONE ACETATE	CHEMBL1152	Small molecule	Approval	DailyMed	8	1	1	Drugs and targets
AZELASTINE HYDROCHLORIDE	CHEMBL1200809	Small molecule	Approval	DailyMed	7	1	1	Drugs and targets

1 to 10 of 47

See all 47 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH1	Histamine H1 receptor	20	Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
NR3C1	Glucocorticoid receptor	9	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
ADRA2A	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
ADRA1A	Adrenergic receptor alpha	1	Adrenergic receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	1	Adrenergic receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	1	Adrenergic receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
C5	Complement C5	1	Complement C5 inhibitor	Phase 1/2	https://conductscience.org/library/genes/727	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials65

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01743027	Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis	Phase 3	902	2014-08-11	Allergic Conjunctivitis	OLOPATADINE, OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01987765	Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea		847	2014-04-29	Conjunctivitis, Allergic	EPINASTINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01479374	Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model	Phase 3	397	2013-05-23	Allergic Conjunctivitis	OLOPATADINE, OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02322216	Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects	Phase 3	383	2016-10-12	Allergic Conjunctivitis	OLOPATADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03494504	ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis	Phase 3	318	2025-02-11	Allergic Conjunctivitis	REPROXALAP	Its record names the disease	ClinicalTrials.gov
NCT01435460	Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)	Phase 3	300	2012-03-13	Seasonal Allergic Conjunctivitis	LOTEPREDNOL ETABONATE, OLOPATADINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01174823	Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients	Phase 2	245	2020-09-14	Allergic Conjunctivitis	BEPOTASTINE BESYLATE	Its record names the disease	ClinicalTrials.gov
NCT01289431	Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis	Phase 2	236	2020-09-04	Conjunctivitis, Allergic	MAPRACORAT	Its record names the disease	ClinicalTrials.gov
NCT05591755	Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis	Phase 3	229	2025-07-01	Seasonal Allergic Conjunctivitis	BRIMONIDINE TARTRATE, KETOTIFEN FUMARATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03479307	A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.	Phase 3	228	2021-12-14	Allergic Conjunctivitis	BILASTINE, KETOTIFEN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 65

See all 65 trials

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Alrex vs Patanol: serious adverse events	1 of 151	0 of 149	300	NCT01435460	Trial comparisons
Bepotastine Besilate Ophthalmic Solution vs Placebo: deaths from any cause	0 of 123	0 of 121	244	NCT01174823	Trial comparisons
Bepotastine Besilate Ophthalmic Solution vs Placebo: serious adverse events	0 of 123	1 of 121	244	NCT01174823	Trial comparisons
Olopatadine 0.1% vs Epinastine 0.05%: serious adverse events	0 of 50	0 of 50	100	NCT02251613	Trial comparisons
NS2 Ophthalmic Drops (0.5%) vs Vehicle Ophthalmic Drops: deaths from any cause	0 of 50	0 of 50	100	NCT02578914	Trial comparisons
NS2 Ophthalmic Drops (0.5%) vs Vehicle Ophthalmic Drops: serious adverse events	0 of 50	0 of 50	100	NCT02578914	Trial comparisons
OTX-DP vs Placebo: deaths from any cause	0 of 48	0 of 48	96	NCT04050865	Trial comparisons
OTX-DP vs Placebo: serious adverse events	0 of 48	0 of 48	96	NCT04050865	Trial comparisons
OTX-DP vs Placebo Vehicle: deaths from any cause	0 of 41	0 of 40	81	NCT02988882	Trial comparisons
OTX-DP vs Placebo Vehicle: serious adverse events	0 of 41	0 of 40	81	NCT02988882	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
16877412	RESULT	1	PubMed
39386177	DERIVED	1	PubMed
39328900	DERIVED	1	PubMed
36811846	DERIVED	1	PubMed
28007090	DERIVED	1	PubMed
27466061	DERIVED	2	PubMed
26266427	DERIVED	1	PubMed
25163405	DERIVED	1	PubMed
23484763	DERIVED	1	PubMed
22991696	DERIVED	2	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005642

GET https://conductscience.org/api/diseases/v1/MONDO_0005642/drugs?page=2

API reference For AI assistants